To improve the clinical utility of cfDNA, Han et al. [80] used a PNA clamp in conjunction with melting curve analysis in PCR to follow both EGFR and KRAS mutations in the plasma of patients with NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.